A groundbreaking, twice-yearly injection for HIV prevention is hailed as a potential ‘game-changer’. However, it is at the centre of a fierce debate regarding affordability. Health activists worldwide implore its manufacturer, Gilead Sciences, to prevent a “missed opportunity for achieving equity.” This twice-yearly HIV jab could revolutionise prevention efforts. But that will only occur if it becomes accessible to all.…